Journal of Southern Medical University ›› 2023, Vol. 43 ›› Issue (3): 368-374.doi: 10.12122/j.issn.1673-4254.2023.03.05

Previous Articles     Next Articles

CD5L is elevated in the serum of patients with candidemia and promotes disease progression in mouse models

WU Xianan, YANG Ming, GUO Wentao, HU Jie, DONG Ke, GAO Zhaowei   

  1. Clinical Laboratory, Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China
  • Online:2023-03-20 Published:2023-03-20

Abstract: Objective To investigate the changes of CD5L levels in patients with candidemia and explore the role of CD5L in progression of candidemia. Methods Twenty healthy control individuals, 27 patients with bacteremia and 35 patients with candidemia were examined for serum CD5L levels using ELISA, and the correlations of CD5L level with other serological indicators were analyzed. A C57BL/6 mouse model of candidemia induced by intravenous injection of Candida albicans were treated with intraperitoneal injection of recombinant CD5L protein, and renal histopathological and serological changes were analyzed to assess renal injures. The effects of CD5L treatment on general condition, fungal burden, of survival of the mice were observed, and the changes in serum IL-6 and IL-8 levels of the mice were detected using ELISA. Results CD5L levels were significantly elevated in patients with candidemia and positively correlated with WBC, BDG, Scr and PCT levels. The mouse model of candidemia also showed significantly increased serum and renal CD5L levels, and CD5L treatment significantly increased fungal burden in the renal tissue, elevated IL-6 and IL-8 levels in the serum and kidney, aggravated renal tissue damage, and reduced survival rate of candidemia mice. Conclusion Serum CD5L levels are increased in patients with candidemia, and treatment with CD5L aggravates candidemia in mouse models.

Key words: candidiasis; CD5L; inflammation; renal injury